US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Super League Gaming Inc.

0.1099

-0.0049-4.27%

Post-market: 0.11300.0031+2.82%19:59 EDT

Volume:4.47M

Turnover:483.20K

Market Cap:3.61M

PE:-0.07

High:0.1143

Open:0.1137

Low:0.1040

Close:0.1148

Loading ...

Overview Company News Filings

Super League Enterprise Lays Off 35% of Workforce

RedHill-Supported Medscape H. Pylori Educational Program to Launch at Major Gastroenterology Congress

AMGEN REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS

Super League Acquires Supersocial, Expanding Brand Partnership Portfolio and Bolstering Business Growth

THOMSON REUTERS

Super League Acquires Supersocial, Expanding Brand Partnership Portfolio and Bolstering Business Growth

Cullinan Therapeutics to Initiate Study of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Sjögren’s Disease in the United States

Autolus Therapeutics Highlights Advancing Autoimmune Pipeline at R&D Investor Event

Galapagos Reports First Quarter 2025 Financial Results, Recent Business Highlights and Near-Term Catalysts

Fate Therapeutics' Lupus Candidate FT819 Gets FDA RMAT Tag

Fate Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus (SLE)

Press Release: Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical Officer

FDA Grants Three Fast Track Tags to Allogene's Autoimmune Disease Drug

Allogene Granted Three U.S. FDA Fast Track Designations (FTD) for ALLO-329, a Next-Generation Dual-Targeted CD19/CD70 Allogeneic CAR T, for the Treatment of Lupus, Myositis and Scleroderma

Super League Enterprise Full Year 2024 Earnings: Misses Expectations

Simply Wall St.

Autolus Therapeutics to Host R&D Investor Event on Wednesday, April 23, 2025

Charles River & Valo Health's Logica Identifies New Lupus Drug Candidate

GRI Bio Bolsters Intellectual Property Portfolio with Granting of Two Global Patents for Europe and Japan

Cabaletta Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Super League Enterprise Inc (SLE) Q4 2024 Earnings Call Highlights: Strategic Shifts and Growth ...

Super League Enterprise Inc reports results for the quarter ended December 31 - Earnings Summary

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/SLE/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SLE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SLE\",,,,,undefined,":{"symbol":"SLE","market":"US","secType":"STK","nameCN":"Super League Gaming Inc.","latestPrice":0.1099,"timestamp":1750104000000,"preClose":0.1148,"halted":0,"volume":4471324,"hourTrading":{"tag":"盘后","latestPrice":0.113,"preClose":0.1099,"latestTime":"19:59 EDT","volume":286196,"amount":31571.889609,"timestamp":1750118362810},"delay":0,"floatShares":29862399,"shares":32824123,"eps":-1.68411,"marketStatus":"Closed","change":-0.0049,"latestTime":"06-16 16:00:00 EDT","open":0.1137,"high":0.1143,"low":0.104,"amount":483200.33504599996,"amplitude":0.089721,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.68411,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1750147200000},"marketStatusCode":5,"adr":0,"listingDate":1551157200000,"exchange":"NASDAQ","adjPreClose":0.1148,"preHourTrading":{"tag":"盘前","latestPrice":0.1145,"preClose":0.1148,"latestTime":"09:28 EDT","volume":68434,"amount":7809.56216144,"timestamp":1750080505691},"postHourTrading":{"tag":"盘后","latestPrice":0.113,"preClose":0.1099,"latestTime":"19:59 EDT","volume":286196,"amount":31571.889609,"timestamp":1750118362810},"volumeRatio":0.863792},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SLE\",,,,,undefined,":{"symbol":"SLE","floatShares":29862399,"roa":"-71.33%","roe":"-1235.06%","lyrEps":-2.351262,"volumeRatio":0.863792,"shares":32824123,"dividePrice":0,"high":0.1143,"amplitude":0.089721,"preClose":0.1148,"low":0.104,"week52Low":0.104,"pbRate":"-1.04","psRate":"0.25","week52High":1.64,"institutionHeld":0,"latestPrice":0.1099,"eps":-1.68411,"divideRate":0,"volume":4471324,"delay":0,"ttmEps":-1.68411,"open":0.1137,"prevYearClose":0.6175,"prevWeekClose":0.1148,"prevMonthClose":0.195,"prevQuarterClose":0.235,"fiveDayClose":0.13,"twentyDayClose":0.1775,"sixtyDayClose":0.3463},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SLE\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2533696983","title":"Super League Enterprise Lays Off 35% of Workforce","url":"https://stock-news.laohu8.com/highlight/detail?id=2533696983","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533696983?lang=en_us&edition=fundamental","pubTime":"2025-05-07 06:21","pubTimestamp":1746570060,"startTime":"0","endTime":"0","summary":"Super League Enterprise said it will undergo a 35% reduction in its workforce and a restructuring of management compensation.As of Dec. 31, the company had 75 full-time and full-time equivalent employees, according to a filing with the Securities and Exchange Commission. Based on that, the layoffs would affect about 26 people. The layoffs were effective April 14.The company said Tuesday the cost reduction measures were necessary for strategic realignment with industry consolidation trends.The company also said its executive chair, chief executive and chief financial officer agreed to a 10% reduction of their respective annual salaries beginning May 1.The measures will help the publisher of playable games reduce operating costs by about $2.7 million this year, which it said will help reach its targeted goal of being EBITDA positive in the fourth quarter.\"Today's announcement reinforces our commitment to streamlining the company's cost structure towards the goal of achieving profitabilit","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLE","BK4077"],"gpt_icon":0},{"id":"2532810145","title":"RedHill-Supported Medscape H. Pylori Educational Program to Launch at Major Gastroenterology Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2532810145","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532810145?lang=en_us&edition=fundamental","pubTime":"2025-05-02 19:00","pubTimestamp":1746183600,"startTime":"0","endTime":"0","summary":"The first part of the program, led by a faculty of William Chey, MD, Vivian Asamoah, MD and Shailja Shah, MD, MPH, will take place May 6 during a major U.S. gastroenterology meeting. H. pylori is classified by the World Health Organization  as a Group 1 carcinogen, being the strongest known risk factor for gastric cancer[1]and a major risk factor for peptic ulcer disease[2]. With almost half the global population infected by H. pylori[3], its treatment represents a billion-dollar market opportunity[4]. RALEIGH, N.C., May 2, 2025 /PRNewswire/ --RedHill Biopharma Ltd.  , a specialty biopharmaceutical company, today announced its support of an independent medical education grant that includes a new two-part H. PyloriCME program, developed by Medscape and designed to advance clinical knowledge and improve patient outcomes. The first part of the program, a livestreamed event entitled \"Let's Get Social About H. pylori Management\" led by William Chey, MD, Vivian Asamoah, MD and Shailja Shah, ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/redhill-supported-medscape-h-pylori-110000775.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/redhill-supported-medscape-h-pylori-110000775.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4124","PPI","IE00BVYPNV92.GBP","LU1481011671.HKD","BK4112","LU0823417653.USD","LU0545562505.USD","LU1481011911.USD","LU2506952170.USD","BK4588","LU1732799900.SGD","BK4077","IE00BVYPNW00.USD","BK4121","SLE","LU2506951958.HKD","LU0823417737.USD","LU0950375773.USD","LU2089283258.USD","LU0795875169.SGD","MAA","LU2133065610.SGD","BK4585","IE00B3T34201.USD","CME","LU0795875086.SGD","RDHL","LU0731783048.USD","LU2506951875.HKD","UAE","LU2506952097.USD","TEN","LU1509826696.USD","LU0912757837.SGD","IE0034235188.USD","LU1116320901.HKD","BK4215","LU0265550359.USD","BK4144","LU1116320737.USD","LU1732800096.USD","LU1228905540.USD","LU0158827948.USD","LU0772969993.USD","LU0265550946.USD","SEER","BK4007","LU1718418525.SGD","IE00B42XCP33.USD","BK4570"],"gpt_icon":0},{"id":"2532683802","title":"AMGEN REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS","url":"https://stock-news.laohu8.com/highlight/detail?id=2532683802","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532683802?lang=en_us&edition=fundamental","pubTime":"2025-05-02 04:01","pubTimestamp":1746129660,"startTime":"0","endTime":"0","summary":"THOUSAND OAKS, Calif., May 1, 2025 /PRNewswire/ -- Amgen  today announced financial results for the first quarter of 2025.\"Demand for our products was strong globally in the first quarter. Ongoing new product launches and successful Phase 3 trial results for several products make us feel confident in our long-term growth prospects,\" said Robert A. Bradway, chairman and chief executive officer.For the first quarter, total revenues increased 9% to $8.1 billion in comparison to the first quarter of 2024.Product sales grew 11%, primarily driven by 14% volume growth, partially offset by 6% lower net selling price. U.S. sales grew 14%.Fourteen products delivered at least double-digit sales growth in the first quarter, includingRepatha , BLINCYTO , TEZSPIRE , EVENITY , TAVNEOS  and UPLIZNA .Non-GAAP EPS increased 24% from $3.96 to $4.90, driven by higher revenues, partially offset by higher operating expenses.Repatha  sales increased 27% year-over-year to $656 million in the first quarter, pr","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/amgen-reports-first-quarter-2025-200100246.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/amgen-reports-first-quarter-2025-200100246.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4096","BK4534","LU2468319806.SGD","BK4205","LU1061106388.HKD","TCS","BK4160","LU2112291526.USD","BK4581","BK4077","IE00BJT1NW94.SGD","TCI","IE0009355771.USD","SG9999001440.SGD","LU2242652126.USD","BK4200","LU0889565916.HKD","IE0002141913.USD","BK4211","BK4233","IE00BFTCPJ56.SGD","LU0320765992.SGD","IE00B2B36J28.USD","LU1057294990.SGD","LU0058720904.USD","PN","LU2089984988.USD","BK4533","LU1023059063.AUD","BK4585","LU1983299246.USD","FCF","TSLP","BK4139","AMGN","SLE","IE00B4R5TH58.HKD","BK4599","MTA","BK4566","LU0868494617.USD","LU0109394709.USD","LU0289739699.SGD","BK4188","MPA","LU0122379950.USD","BK4588","GIPR","LU2242646821.SGD"],"gpt_icon":0},{"id":"2532079592","title":"Super League Acquires Supersocial, Expanding Brand Partnership Portfolio and Bolstering Business Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2532079592","media":"THOMSON REUTERS","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532079592?lang=en_us&edition=fundamental","pubTime":"2025-05-01 20:00","pubTimestamp":1746100802,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250501:nTUA4TBB8S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SLE","BK4077"],"gpt_icon":0},{"id":"2532079789","title":"Super League Acquires Supersocial, Expanding Brand Partnership Portfolio and Bolstering Business Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2532079789","media":"GlobeNewswire","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532079789?lang=en_us&edition=fundamental","pubTime":"2025-05-01 20:00","pubTimestamp":1746100800,"startTime":"0","endTime":"0","summary":"Acquisition further solidifies Super League as a leading provider of effective solutions that make brands playable within mobile games and the world’s largest immersive platforms. SANTA MONICA, Calif., May 01, 2025  -- Super League  , a leader in engaging audiences through playable media, content, and experiences, announced today the acquisition of Supersocial, an award-winning production studio and creative agency that has been a pioneer on the Roblox platform since its founding in 2020 by Yonatan Raz-Fridman , Pedro Romi, Luiza Justus, and Tatiana Wlasek. With this accretive acquisition, Super League expands its impressive roster of partnerships and reinforces the Company’s mission to connect brands with passionate consumer audiences through the power of play.Super League  is redefining how brands connect with consumers through the power of playable media. The Company provides global brands with ads, c","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/super-league-acquires-supersocial-expanding-120000125.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","BK4547","BK4077","BK4554","SLE","BK4085","BK4565","LU0348723411.USD","BK4598","RBLX","BK4535","LU1861558580.USD","LU1861559042.SGD","BK4585","BK4551"],"gpt_icon":0},{"id":"2531786662","title":"Cullinan Therapeutics to Initiate Study of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Sjögren’s Disease in the United States","url":"https://stock-news.laohu8.com/highlight/detail?id=2531786662","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531786662?lang=en_us&edition=fundamental","pubTime":"2025-04-29 19:00","pubTimestamp":1745924400,"startTime":"0","endTime":"0","summary":"CLN-978 is the first and only development-stage CD19 T cell engager to receive U.S. FDA IND clearance in autoimmune diseases. Sjgren’s disease represents the third indication under development for CLN-978, and is a disease with high unmet need and no currently approved therapies. CAMBRIDGE, Mass., April 29, 2025  -- Cullinan Therapeutics, Inc., a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced that the Company is initiating a study of CLN-978 in patients with Sjgren’s disease  in the U.S. The Company previously received U.S. Food and Drug Administration  Investigational New Drug  Application clearance to study the CD19 T cell engager in patients with moderate to severe systemic lupus erythematosus  and European Medicines Agency  approval to study CLN-978 in active, difficult-to-treat rheumatoid arthritis.“There are an estimated four million Americans living with Sjgren’s disease, yet it is underdiagnosed","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cullinan-therapeutics-initiate-study-cln-110000913.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SLE","UBCP","BK4077","BK4211","ACR","BK4139","CGEM","BK4110"],"gpt_icon":0},{"id":"2529412663","title":"Autolus Therapeutics Highlights Advancing Autoimmune Pipeline at R&D Investor Event","url":"https://stock-news.laohu8.com/highlight/detail?id=2529412663","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529412663?lang=en_us&edition=fundamental","pubTime":"2025-04-24 04:05","pubTimestamp":1745438700,"startTime":"0","endTime":"0","summary":"Company outlined potential for value creation driven by obe-cel across multiple B cell driven malignancies and autoimmune diseases, including acute lymphoblastic leukemia , lupus nephritis  and multiple sclerosis . Preliminary data in initial six patient cohort treated in Phase 1 trial in systemic lupus erythematosus  support progressing obe-cel into a planned Phase 2 pivotal study in lupus nephritis; first patient expected to be dosed in Phase 2 trial by year-end 2025. Company plans to advance obe-cel in progressive forms of multiple sclerosis ; first patient expected to be dosed in Phase 1 trial by year-end 2025. LONDON, April 23, 2025  -- Autolus Therapeutics plc, an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, today presented updates on its development pipeline and plans for expansion in autoimmune diseases at an R&D investor event.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/autolus-therapeutics-highlights-advancing-autoimmune-200500705.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2357305700.SGD","LU2028103732.USD","LU0158827948.USD","BK4006","LU0795875086.SGD","LU2111349929.HKD","LU1074936037.SGD","BK4581","LU1668664300.SGD","BK4504","LU0267386448.USD","LU1732799900.SGD","IE0031619046.USD","BK4585","BK4022","IE00BZ1G4Q59.USD","LU1989772840.SGD","LU0314104364.USD","BK4107","LU1162221912.USD","BK4516","BK4139","LU1363072403.SGD","LU0320765646.SGD","IE00B7SZL793.SGD","LU0106261372.USD","LU2133065610.SGD","BK4127","ALL","BK4077","LU0971096721.USD","LU1720051017.SGD","LU2089284900.SGD","IE00B19Z4B17.USD","LU0795875169.SGD","LU1571399168.USD","LU2065731478.USD","LU2347655156.SGD","AUTL","LU0158827781.USD","LU1699723380.USD","CRS","LU0106831901.USD","IE00B66KJ199.SGD","LU0912757837.SGD","LENZ","BK4534","SLE","UCL","CAR"],"gpt_icon":0},{"id":"2529668156","title":"Galapagos Reports First Quarter 2025 Financial Results, Recent Business Highlights and Near-Term Catalysts","url":"https://stock-news.laohu8.com/highlight/detail?id=2529668156","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529668156?lang=en_us&edition=fundamental","pubTime":"2025-04-24 04:01","pubTimestamp":1745438460,"startTime":"0","endTime":"0","summary":"First U.S. patient dosed in ATALANTA-1 study of GLPG5101. Mantle cell lymphoma , a high-unmet-need hematological malignancy, selected as lead indication for the GLPG5101 program; Pivotal development planned to start in 2026 and aiming for approval in 2028. Executive leadership changes with Dr. Paul Stoffels retiring as CEO upon appointment of his successor while continuing as Chair of the Board, Thad Huston departing as CFO/COO on August 1, 2025, and Henry Gosebruch appointed Founding CEO of Galapagos subsidiary SpinCo. Management to host conference call and webcast tomorrow, April 24, 2025, at 14:00 CET / 08:00 EDT. Mechelen, Belgium; April 23, 2025, 22:01 CET; regulated information – GalapagosNV , a global biotechnology company dedicated to transforming patient outcomes through life-changing science and innovation, today reported its financial and operational results for the first quarter of 2025.FIRST QUARTER 2025, RECENT BUSINESS UPDATE AND NEAR-TERM CATALYSTSClinical Pipeline: N","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/galapagos-reports-first-quarter-2025-200100727.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4546","SLE","BK4077","BK4161","BK4139","GLPG","DM"],"gpt_icon":0},{"id":"2527015440","title":"Fate Therapeutics' Lupus Candidate FT819 Gets FDA RMAT Tag","url":"https://stock-news.laohu8.com/highlight/detail?id=2527015440","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527015440?lang=en_us&edition=fundamental","pubTime":"2025-04-15 22:42","pubTimestamp":1744728120,"startTime":"0","endTime":"0","summary":"Fate Therapeutics FATE recently announced that the FDA has granted the Regenerative Medicine Advanced Therapy  designation to its investigational pipeline candidate FT819 for the treatment of active moderate to severe systemic lupus erythematosus , including lupus nephritis.The RMAT designation provides the candidate with increased opportunities to meet FDA officials, as well as arrange early meetings to discuss potential surrogate or intermediate endpoints. It opens up early interactions between the FDA and sponsors to facilitate accelerated approval and potential priority review of a product’s biologics license application.FT819 is an off-the-shelf, iPSC-derived CAR T-cell product candidate comprised of CD8αβ+ T cells with a memory phenotype and high CXCR4 expression to promote tissue trafficking.The latest RMAT designation by the FDA underlines the potential of FT819 to address an area of significant unmet medical needs.Year to date, shares of Fate Therapeutics have plunged 44% comp","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fate-therapeutics-lupus-candidate-ft819-144200510.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4533","IE00BN0W2W23.USD","LU0823416689.USD","BK4139","BK4007","BK4077","LU0320765992.SGD","IE00BN0W2V16.EUR","BK4532","LU0109394709.USD","JAZZ","ADMA","IE00BN0W2T93.GBP","FATE","LU0889565916.HKD","KRYS","SLE"],"gpt_icon":0},{"id":"2527549951","title":"Fate Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus (SLE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2527549951","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527549951?lang=en_us&edition=fundamental","pubTime":"2025-04-14 20:00","pubTimestamp":1744632000,"startTime":"0","endTime":"0","summary":"– Recognizes potential of off-the-shelf CAR T-cell therapy to address significant unmet need and enables increased dialogue with FDA throughout the development process. – RMAT review by FDA included initial clinical safety and activity data from ongoing Phase 1 study of FT819 in SLE. SAN DIEGO, April 14, 2025  -- Fate Therapeutics, Inc. , a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem cell -derived off-the-shelf cellular immunotherapies to patients, today announced that the U.S. Food and Drug Administration  granted Regenerative Medicine Advanced Therapy  designation to FT819, an investigational, off-the-shelf, iPSC-derived CAR T-cell therapy in Phase 1 clinical development for the treatment of active moderate to severe systemic lupus erythematosus , including lupus nephritis .The RMAT designation was established under the 21st Century Cures Act to expedite the development and review of regenerative medicine therapies for serious","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fate-therapeutics-receives-regenerative-medicine-120000379.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE0031619046.USD","BK4139","BK4077","AEIS","FATE","IE00B7SZL793.SGD","BK4157","IE00B66KJ199.SGD","IE00B19Z4B17.USD","SLE"],"gpt_icon":0},{"id":"2526384049","title":"Press Release: Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2526384049","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526384049?lang=en_us&edition=fundamental","pubTime":"2025-04-09 04:05","pubTimestamp":1744142700,"startTime":"0","endTime":"0","summary":"Dr. Banerjee's appointment culminates Artiva's efforts to build a seasoned development team with strong expertise in autoimmune diseases and cell therapy. Dr. Banerjee added, \"Artiva is leading the development of NK cell treatments for autoimmune disease, with the potential to offer a much-needed, long-term therapeutic option with an accessibility and safety profile that enables broad use in a community setting. The robust B-cell depletion seen with AlloNK through enhanced antibody-directed killing of cells in non-Hodgkin lymphoma bodes well for our opportunity to deeply deplete B-cells in patients with autoimmune diseases and to bring about meaningful clinical improvements and medication reductions. Artiva has built a very seasoned development team, and I am excited to lead the effort to further define the indications where AlloNK can be most impactful, and to help drive the program towards late-stage development.\"","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IIM","BK4022","ARTV","R","RA","BK4077","BK4232","BK4139","BMS","SLE"],"gpt_icon":0},{"id":"2525318890","title":"FDA Grants Three Fast Track Tags to Allogene's Autoimmune Disease Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2525318890","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525318890?lang=en_us&edition=fundamental","pubTime":"2025-04-08 18:46","pubTimestamp":1744109160,"startTime":"0","endTime":"0","summary":"Allogene Therapeutics ALLO announced that the FDA has granted three fast track designations to its investigational CRISPR-based allogeneic CAR-T therapy, ALLO-329.These designations apply to three autoimmune diseases — systemic lupus erythematosus , idiopathic inflammatory myopathy  and diffuse systemic sclerosis .How Does the Fast Track Tag Benefit ALLO’s Drug Development?Fast track designation is designed to facilitate the development and expedite the review of drugs that treat serious conditions, meet an unmet medical need, or offer a potential advantage over existing treatments. Per the FDA, the purpose of granting this designation is to ‘get important new drugs to the patient earlier.’。In the past 60 days, estimates for CytomX Therapeutics’ 2025 EPS have improved from a loss of 31 cents to a profit of 25 cents. During the same timeframe, estimates for loss per share for 2026 have","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fda-grants-three-fast-track-104600523.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4077","BK4104","IIM","BK4588","SLE","BK4585","IE00BYQQ9H92.USD","IE00B5TLWC47.USD","IE00BFXG0V08.USD","BK4567","BK4139","ANIP","CTMX","ALLO","BK4007","ETNB","BK4505","FAST"],"gpt_icon":0},{"id":"2525048864","title":"Allogene Granted Three U.S. FDA Fast Track Designations (FTD) for ALLO-329, a Next-Generation Dual-Targeted CD19/CD70 Allogeneic CAR T, for the Treatment of Lupus, Myositis and Scleroderma","url":"https://stock-news.laohu8.com/highlight/detail?id=2525048864","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525048864?lang=en_us&edition=fundamental","pubTime":"2025-04-07 20:30","pubTimestamp":1744029000,"startTime":"0","endTime":"0","summary":"Designations Follow Recent Investigational New Drug (IND) Application Clearance for the RESOLUTION Basket Study of ALLO-329 in RheumatologyDual CD19/CD70 CAR T Specifically Designed to Enhance Therape","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/07/3056719/0/en/Allogene-Granted-Three-U-S-FDA-Fast-Track-Designations-FTD-for-ALLO-329-a-Next-Generation-Dual-Targeted-CD19-CD70-Allogeneic-CAR-T-for-the-Treatment-of-Lupus-Myositis-and-Scleroder.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BFXG0V08.USD","BK4505","BK4139","SLE","IE00BYQQ9H92.USD","BK4077","BK4585","FAST","ALLO","BK4022","CAR","BK4567","IIM","BK4104","BK4230","IE00B5TLWC47.USD","BK4588"],"gpt_icon":0},{"id":"2525732917","title":"Super League Enterprise Full Year 2024 Earnings: Misses Expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=2525732917","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525732917?lang=en_us&edition=fundamental","pubTime":"2025-04-05 02:59","pubTimestamp":1743793184,"startTime":"0","endTime":"0","summary":"We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.NasdaqCM:SLE Earnings and Revenue History April 4th 2025. All figures shown in the chart above are for the trailing 12 month  period. Revenue missed analyst estimates by 11%. Earnings per share  also missed analyst estimates by 20%.Looking ahead, revenue is forecast to grow 17% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Interactive Media and Services industry in the US.Performance of the American Interactive Media and Services industry.The company's shares are down 41% from a week ago.We should say that we've discovered 5 warning signs for Super League Enterprise (3 don't sit too well with us!) that you should be aware of before investing here.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/super-league-enterprise-full-2024-185944978.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SLE"],"gpt_icon":0},{"id":"2524419418","title":"Autolus Therapeutics to Host R&D Investor Event on Wednesday, April 23, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2524419418","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524419418?lang=en_us&edition=fundamental","pubTime":"2025-04-01 19:00","pubTimestamp":1743505200,"startTime":"0","endTime":"0","summary":"LONDON, April  01, 2025  (GLOBE NEWSWIRE) -- Autolus Therapeutics plc(Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation progra","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/01/3053144/0/en/Autolus-Therapeutics-to-Host-R-D-Investor-Event-on-Wednesday-April-23-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HST","BK4588","SLE","BK4139","BK4218","LENZ","BK4585","BK4077","BK4181"],"gpt_icon":0},{"id":"2523926560","title":"Charles River & Valo Health's Logica Identifies New Lupus Drug Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2523926560","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523926560?lang=en_us&edition=fundamental","pubTime":"2025-03-31 21:20","pubTimestamp":1743427200,"startTime":"0","endTime":"0","summary":"Charles River Laboratories International, Inc.CRL and Valo Health, Inc. recently announced an advanced product candidate for the treatment of different forms of lupus and other autoimmune indications with significant unmet needs. The discovery marks the first using Logica, an artificial intelligence -powered drug development solution that translates biological insights into optimized preclinical assets.Alongside Valo Health and Flagship Pioneering’s in-house drug development unit, Pioneering Medicines, Charles River looks forward to further leveraging the power of Logica to advance this program into lead optimization.Importance of Charles River and Valo’s Combined Offering. Logica, the result of a strategic collaboration between Charles River and Valo Health, is the industry’s first computation-powered, unified target-to-candidate offering. The platform leverages the integration of Valo Health’s AI-powered Opal Computational Platform and Charles River’s leading expertise in drug discov","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/charles-river-valo-healths-logica-132000618.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1548497426.USD","BK4530","BIO","LU1791710400.SGD","LU1712237335.SGD","LU2298321311.HKD","LU1691799644.USD","LU1721429402.USD","LU0957791311.USD","IE00BFTCPJ56.SGD","LU1169590202.USD","LU1914381329.SGD","IE00B19Z8X17.USD","LU2125909247.SGD","LU2211815571.USD","IE0009355771.USD","LU1923621640.USD","LU1983299246.USD","BK4585","BK4077","LU2468319806.SGD","CRL","LU2764262908.HKD","SG9999002232.USD","SLE","BK4535","LU1633808545.USD","LU1989771016.USD","ABT","LU2211814178.USD","LU1854103824.USD","IE00BJJMRZ35.SGD","LU2092937221.SGD","BK4566","IE00B2B36J28.USD","LU2764263203.CNY","LU2125909593.SGD","BK4548","BK4533","LU0096362180.USD","BK4568","LU0640476718.USD","BK4504","TMO","LU1670628061.USD","LU2764263039.SGD","LU2041044095.USD","LU1023059063.AUD","LU0234572021.USD","SG9999004303.SGD"],"gpt_icon":0},{"id":"2523094592","title":"GRI Bio Bolsters Intellectual Property Portfolio with Granting of Two Global Patents for Europe and Japan","url":"https://stock-news.laohu8.com/highlight/detail?id=2523094592","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523094592?lang=en_us&edition=fundamental","pubTime":"2025-03-31 20:00","pubTimestamp":1743422400,"startTime":"0","endTime":"0","summary":"Company committed to building a robust global patent estate across its innovative pipeline of NKT cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases LA JOLLA, CA, Marc","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/31/3052210/0/en/GRI-Bio-Bolsters-Intellectual-Property-Portfolio-with-Granting-of-Two-Global-Patents-for-Europe-and-Japan.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4077","BK4007","GRI","BK4139","SLE"],"gpt_icon":0},{"id":"2523171969","title":"Cabaletta Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2523171969","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523171969?lang=en_us&edition=fundamental","pubTime":"2025-03-31 19:00","pubTimestamp":1743418800,"startTime":"0","endTime":"0","summary":"– FDA meeting to align on myositis registrational trial designs for rese-cel in 1H25 on track – – Enrolling approximately one patient per week across the RESET clinical development program since ACR C","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/31/3052139/0/en/Cabaletta-Bio-Reports-Fourth-Quarter-and-Full-Year-2024-Financial-Results-and-Provides-Business-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0106831901.USD","BK4581","SLE","BK4516","LU0106261372.USD","LU0314104364.USD","LU0098860793.USD","LU1668664300.SGD","BK4563","LU0225283273.USD","LU0267386448.USD","LU2023251221.USD","LU1720051108.HKD","LU2347655156.SGD","BK4585","LU1363072403.SGD","BK4077","LU1989772923.USD","LU2133065610.SGD","LU2357305700.SGD","LU0158827781.USD","BK4588","LU1548497426.USD","LU0320765646.SGD","LU1989772840.SGD","LU2089283258.USD","BK4139","LU2089284900.SGD","BK4127","IE00BKVL7J92.USD","LU0795875086.SGD","LU2028103732.USD","LU1162221912.USD","LU2111349929.HKD","LU2271345857.HKD","BK4534","CABA","BK4504","LU1732799900.SGD","LU0795875169.SGD","LU0971096721.USD","LU1720051017.SGD","LU0006306889.USD","IE00BZ1G4Q59.USD","LU0158827948.USD","LU1074936037.SGD","CDMO","IMNM","LU1732800096.USD","LU0912757837.SGD"],"gpt_icon":0},{"id":"2523119796","title":"Super League Enterprise Inc (SLE) Q4 2024 Earnings Call Highlights: Strategic Shifts and Growth ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2523119796","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523119796?lang=en_us&edition=fundamental","pubTime":"2025-03-30 03:01","pubTimestamp":1743274886,"startTime":"0","endTime":"0","summary":"Revenue Diversification: Positive signs in Q1 with revenue diversification kicking in.Margins: Margins are recovering with higher-margin products added to the portfolio.Active Pursuits: Approximately $20 million in active pursuits across 77 unique programs.EBITDA Goal: Aim to be EBITDA positive in Q4.Cost Structure: Aggressively attacking cost structure to align with breakeven imperative.GuruFocus has detected 6 Warning Signs with SLE.For the complete transcript of the earnings call, please refer to the full earnings call transcript.Super League Enterprise Inc  is optimistic about optimizing its business model to deliver meaningful shareholder value despite facing micro-cap and macroeconomic challenges.Revenue diversification is underway, with mobile games becoming a significant growth area, contributing to 16% of revenue in Q4 and expected to reach 20% in Q1.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/super-league-enterprise-inc-sle-190126765.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["RBLX","SLE"],"gpt_icon":0},{"id":"2522577543","title":"Super League Enterprise Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2522577543","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522577543?lang=en_us&edition=fundamental","pubTime":"2025-03-28 21:31","pubTimestamp":1743168675,"startTime":"0","endTime":"0","summary":"Super League Enterprise Inc reports results for the quarter ended December 31 - Earnings SummarySuper League Enterprise Inc SLE.OQ reported a quarterly adjusted loss of 45 cents per share for the quar","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250328:nL5N3QB14L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLE"],"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":3,"totalSize":101,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SLE\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-15","symbol":"SLE","fiscalQuarterEnding":"2025/03","expectedEps":-0.3,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1747281600000,"reportTimeType":"post","actualEps":-0.25},{"market":"US","date":"2025-03-28","symbol":"SLE","fiscalQuarterEnding":"2024/12","expectedEps":-0.35,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1743134400000,"reportTimeType":"pre","actualEps":-0.45},{"market":"US","date":"2024-11-14","symbol":"SLE","fiscalQuarterEnding":"2024/09","expectedEps":-0.28,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731560400000,"reportTimeType":"post","actualEps":-0.54},{"market":"US","date":"2024-08-14","symbol":"SLE","fiscalQuarterEnding":"2024/06","expectedEps":-0.62,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1723608000000,"reportTimeType":"post","actualEps":-0.6},{"market":"US","date":"2024-05-15","symbol":"SLE","fiscalQuarterEnding":"2024/03","expectedEps":-1.18,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1715745600000,"reportTimeType":"post","actualEps":1}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SLE\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SLE\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":2,"updateTime":1694059200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SLE\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SLE","date":"2025-06-13","current":-0.226363,"percent":0.703614,"low":-0.555206,"twenty":-0.347212,"median":-0.28021,"eighty":-0.210038,"high":-0.044016,"avg":-0.274466,"sd":0.104139,"marketCap":3532387},"quantilePoints":[{"date":"2023-09-15","current":-0.077235,"twenty":-0.086128,"median":-0.080205,"eighty":-0.078423,"marketCap":6401787},{"date":"2023-09-22","current":-0.075989,"twenty":-0.079611,"median":-0.075989,"eighty":-0.069678,"marketCap":6298532},{"date":"2023-09-29","current":-0.074744,"twenty":-0.077567,"median":-0.075367,"eighty":-0.07167,"marketCap":6195277},{"date":"2023-10-06","current":-0.072252,"twenty":-0.076986,"median":-0.074328,"eighty":-0.071255,"marketCap":5988768},{"date":"2023-10-13","current":-0.056058,"twenty":-0.075906,"median":-0.072252,"eighty":-0.068681,"marketCap":4646458},{"date":"2023-10-20","current":-0.059795,"twenty":-0.075491,"median":-0.072252,"eighty":-0.064944,"marketCap":4956222},{"date":"2023-10-27","current":-0.044846,"twenty":-0.075325,"median":-0.071006,"eighty":-0.062951,"marketCap":3717166},{"date":"2023-11-03","current":-0.051075,"twenty":-0.07491,"median":-0.068931,"eighty":-0.055726,"marketCap":4233439},{"date":"2023-11-10","current":-0.053151,"twenty":-0.074494,"median":-0.066439,"eighty":-0.051324,"marketCap":4405530},{"date":"2023-11-17","current":-0.15932,"twenty":-0.07491,"median":-0.066023,"eighty":-0.051324,"marketCap":5300404},{"date":"2023-11-24","current":-0.213857,"twenty":-0.076737,"median":-0.067685,"eighty":-0.052154,"marketCap":7114796},{"date":"2023-12-01","current":-0.221494,"twenty":-0.122932,"median":-0.069346,"eighty":-0.053317,"marketCap":7368896},{"date":"2023-12-08","current":-0.2024,"twenty":-0.203928,"median":-0.072252,"eighty":-0.053898,"marketCap":6733646},{"date":"2023-12-15","current":-0.235497,"twenty":-0.21182,"median":-0.072252,"eighty":-0.054563,"marketCap":7834746},{"date":"2023-12-22","current":-0.217675,"twenty":-0.215894,"median":-0.074536,"eighty":-0.054978,"marketCap":7241846},{"date":"2023-12-29","current":-0.203673,"twenty":-0.216403,"median":-0.075159,"eighty":-0.055227,"marketCap":6775996},{"date":"2024-01-05","current":-0.2024,"twenty":-0.216403,"median":-0.075782,"eighty":-0.055726,"marketCap":6733646},{"date":"2024-01-12","current":-0.210038,"twenty":-0.216403,"median":-0.07765,"eighty":-0.056058,"marketCap":6987746},{"date":"2024-01-19","current":-0.220221,"twenty":-0.217675,"median":-0.090076,"eighty":-0.057553,"marketCap":7326546},{"date":"2024-01-26","current":-0.238043,"twenty":-0.218439,"median":-0.176404,"eighty":-0.060459,"marketCap":7919446},{"date":"2024-02-02","current":-0.263515,"twenty":-0.222258,"median":-0.2024,"eighty":-0.062452,"marketCap":8766869},{"date":"2024-02-09","current":-0.288961,"twenty":-0.22404,"median":-0.203673,"eighty":-0.064279,"marketCap":9613445},{"date":"2024-02-16","current":-0.328423,"twenty":-0.227604,"median":-0.204946,"eighty":-0.06511,"marketCap":10926294},{"date":"2024-02-23","current":-0.31442,"twenty":-0.235497,"median":-0.207492,"eighty":-0.065774,"marketCap":10460445},{"date":"2024-03-01","current":-0.306782,"twenty":-0.258166,"median":-0.208765,"eighty":-0.066522,"marketCap":10206345},{"date":"2024-03-08","current":-0.254591,"twenty":-0.26656,"median":-0.210038,"eighty":-0.067186,"marketCap":8469996},{"date":"2024-03-15","current":-0.225313,"twenty":-0.263003,"median":-0.213857,"eighty":-0.068681,"marketCap":7495946},{"date":"2024-03-22","current":-0.349526,"twenty":-0.275749,"median":-0.21513,"eighty":-0.069346,"marketCap":11628396},{"date":"2024-03-28","current":-0.4417,"twenty":-0.283869,"median":-0.216403,"eighty":-0.069346,"marketCap":13396770},{"date":"2024-04-05","current":-0.367495,"twenty":-0.286708,"median":-0.217039,"eighty":-0.071006,"marketCap":11146112},{"date":"2024-04-12","current":-0.300356,"twenty":-0.297872,"median":-0.218948,"eighty":-0.072252,"marketCap":9109803},{"date":"2024-04-19","current":-0.288,"twenty":-0.297872,"median":-0.220857,"eighty":-0.072252,"marketCap":8735051},{"date":"2024-04-26","current":-0.293245,"twenty":-0.295326,"median":-0.222767,"eighty":-0.072252,"marketCap":8894120},{"date":"2024-05-03","current":-0.294239,"twenty":-0.295326,"median":-0.22404,"eighty":-0.072252,"marketCap":8924269},{"date":"2024-05-10","current":-0.276346,"twenty":-0.294239,"median":-0.22404,"eighty":-0.073498,"marketCap":8381577},{"date":"2024-05-17","current":-0.295605,"twenty":-0.295605,"median":-0.227222,"eighty":-0.074328,"marketCap":8381577},{"date":"2024-05-24","current":-0.265832,"twenty":-0.295326,"median":-0.232951,"eighty":-0.074744,"marketCap":7537390},{"date":"2024-05-31","current":-0.292406,"twenty":-0.294456,"median":-0.235497,"eighty":-0.075076,"marketCap":8290883},{"date":"2024-06-07","current":-0.271353,"twenty":-0.294239,"median":-0.238043,"eighty":-0.075491,"marketCap":7693940},{"date":"2024-06-14","current":-0.252339,"twenty":-0.293643,"median":-0.245044,"eighty":-0.075823,"marketCap":7154833},{"date":"2024-06-21","current":-0.201872,"twenty":-0.292909,"median":-0.238043,"eighty":-0.076487,"marketCap":5723866},{"date":"2024-06-28","current":-0.196825,"twenty":-0.292574,"median":-0.238043,"eighty":-0.076986,"marketCap":5580762},{"date":"2024-07-05","current":-0.214489,"twenty":-0.291076,"median":-0.236984,"eighty":-0.077484,"marketCap":6081608},{"date":"2024-07-12","current":-0.257386,"twenty":-0.29019,"median":-0.238043,"eighty":-0.079183,"marketCap":7297929},{"date":"2024-07-15","current":-0.26748,"twenty":-0.29019,"median":-0.238043,"eighty":-0.079694,"marketCap":7584122},{"date":"2024-08-02","current":-0.322994,"twenty":-0.29019,"median":-0.238043,"eighty":-0.080205,"marketCap":9158186},{"date":"2024-08-09","current":-0.280097,"twenty":-0.291452,"median":-0.25,"eighty":-0.090076,"marketCap":7941864},{"date":"2024-08-16","current":-0.331284,"twenty":-0.291452,"median":-0.254591,"eighty":-0.144836,"marketCap":7941864},{"date":"2024-08-23","current":-0.53758,"twenty":-0.294239,"median":-0.257262,"eighty":-0.15932,"marketCap":12887411},{"date":"2024-08-30","current":-0.506735,"twenty":-0.296227,"median":-0.259657,"eighty":-0.193489,"marketCap":12147969},{"date":"2024-09-06","current":-0.478094,"twenty":-0.298215,"median":-0.261996,"eighty":-0.196158,"marketCap":11461345},{"date":"2024-09-13","current":-0.387888,"twenty":-0.305764,"median":-0.26512,"eighty":-0.200267,"marketCap":9298829},{"date":"2024-09-20","current":-0.279367,"twenty":-0.307264,"median":-0.267321,"eighty":-0.201723,"marketCap":6697270},{"date":"2024-09-27","current":-0.280954,"twenty":-0.305764,"median":-0.2674,"eighty":-0.201872,"marketCap":6735311},{"date":"2024-10-04","current":-0.340548,"twenty":-0.30919,"median":-0.267958,"eighty":-0.202294,"marketCap":8163949},{"date":"2024-10-11","current":-0.449597,"twenty":-0.311325,"median":-0.268116,"eighty":-0.2024,"marketCap":10778189},{"date":"2024-10-18","current":-0.388813,"twenty":-0.315693,"median":-0.269014,"eighty":-0.203418,"marketCap":9321020},{"date":"2024-10-25","current":-0.405078,"twenty":-0.328743,"median":-0.270264,"eighty":-0.203673,"marketCap":9710936},{"date":"2024-10-31","current":-0.447393,"twenty":-0.331576,"median":-0.271783,"eighty":-0.204227,"marketCap":10725354},{"date":"2024-11-08","current":-0.410367,"twenty":-0.346526,"median":-0.273854,"eighty":-0.204806,"marketCap":9837739},{"date":"2024-11-15","current":-0.436374,"twenty":-0.369724,"median":-0.275294,"eighty":-0.204946,"marketCap":10461183},{"date":"2024-11-22","current":-0.261371,"twenty":-0.368039,"median":-0.276231,"eighty":-0.20571,"marketCap":6435212},{"date":"2024-11-29","current":-0.294604,"twenty":-0.364668,"median":-0.276346,"eighty":-0.206728,"marketCap":7253456},{"date":"2024-12-06","current":-0.323013,"twenty":-0.356067,"median":-0.277855,"eighty":-0.207492,"marketCap":7952897},{"date":"2024-12-13","current":-0.312281,"twenty":-0.347526,"median":-0.28005,"eighty":-0.208001,"marketCap":7688663},{"date":"2024-12-20","current":-0.321435,"twenty":-0.346138,"median":-0.280097,"eighty":-0.208765,"marketCap":7914039},{"date":"2024-12-27","current":-0.339269,"twenty":-0.34373,"median":-0.28052,"eighty":-0.20902,"marketCap":8353132},{"date":"2025-01-03","current":-0.336691,"twenty":-0.344526,"median":-0.281632,"eighty":-0.210038,"marketCap":8289664},{"date":"2025-01-10","current":-0.383512,"twenty":-0.351706,"median":-0.282822,"eighty":-0.210038,"marketCap":9442446},{"date":"2025-01-17","current":-0.309808,"twenty":-0.347717,"median":-0.284299,"eighty":-0.211096,"marketCap":7627786},{"date":"2025-01-24","current":-0.310545,"twenty":-0.347233,"median":-0.284972,"eighty":-0.212858,"marketCap":7645920},{"date":"2025-01-31","current":-0.354781,"twenty":-0.353001,"median":-0.285142,"eighty":-0.213857,"marketCap":8735057},{"date":"2025-02-07","current":-0.319937,"twenty":-0.350441,"median":-0.285388,"eighty":-0.213857,"marketCap":7877163},{"date":"2025-02-14","current":-0.31412,"twenty":-0.349224,"median":-0.286351,"eighty":-0.213857,"marketCap":7733942},{"date":"2025-02-21","current":-0.308303,"twenty":-0.349022,"median":-0.286674,"eighty":-0.21411,"marketCap":7590720},{"date":"2025-02-28","current":-0.232681,"twenty":-0.348999,"median":-0.28664,"eighty":-0.214489,"marketCap":5728846},{"date":"2025-03-07","current":-0.21936,"twenty":-0.348284,"median":-0.285948,"eighty":-0.214489,"marketCap":5400869},{"date":"2025-03-14","current":-0.209704,"twenty":-0.347244,"median":-0.285144,"eighty":-0.213941,"marketCap":5163122},{"date":"2025-03-21","current":-0.201444,"twenty":-0.347002,"median":-0.285098,"eighty":-0.212359,"marketCap":4959748},{"date":"2025-03-28","current":-0.230354,"twenty":-0.345822,"median":-0.284304,"eighty":-0.212359,"marketCap":5671557},{"date":"2025-04-04","current":-0.234475,"twenty":-0.342935,"median":-0.283459,"eighty":-0.210567,"marketCap":3900496},{"date":"2025-04-11","current":-0.236161,"twenty":-0.340036,"median":-0.28231,"eighty":-0.212359,"marketCap":3928533},{"date":"2025-04-17","current":-0.236161,"twenty":-0.338893,"median":-0.280718,"eighty":-0.213857,"marketCap":3928533},{"date":"2025-04-25","current":-0.369736,"twenty":-0.338893,"median":-0.280836,"eighty":-0.213857,"marketCap":6150554},{"date":"2025-05-02","current":-0.394848,"twenty":-0.347107,"median":-0.282596,"eighty":-0.213857,"marketCap":6568294},{"date":"2025-05-09","current":-0.347723,"twenty":-0.34901,"median":-0.284084,"eighty":-0.213899,"marketCap":5784365},{"date":"2025-05-16","current":-0.174182,"twenty":-0.348716,"median":-0.282596,"eighty":-0.211859,"marketCap":2897515},{"date":"2025-05-23","current":-0.187657,"twenty":-0.347631,"median":-0.280836,"eighty":-0.209762,"marketCap":2928392},{"date":"2025-05-30","current":-0.243307,"twenty":-0.347723,"median":-0.280836,"eighty":-0.209995,"marketCap":3796802},{"date":"2025-06-06","current":-0.252949,"twenty":-0.347265,"median":-0.280718,"eighty":-0.210038,"marketCap":3947265},{"date":"2025-06-13","current":-0.226363,"twenty":-0.347212,"median":-0.28021,"eighty":-0.210038,"marketCap":3532387}],"updateTime":1750078066206}}}